Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Cymab ApS
APS
Active
CVR 39859173
Ole Maaløes Vej 3, 2200
København N
Manufacture of pharmaceutical preparations
·
NACE 2120
Est. 2018 · 7 years old
2 employees
Monitor
Share
Denmark
/
Companies
/
Manufacture of pharmaceutical preparations
/
Cymab ApS
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
DKK millions
0M
-2M
-3M
-5M
-6M
-1M
2021
0M
+100%
2022
-1M
-100%
2023
-2M
-100%
2024
-5M
-150%
2025
EBITDA
DKK millions
0M
-3M
-6M
-8M
-11M
-1M
2021
-2M
-100%
2022
-3M
-50%
2023
-6M
-100%
2024
-9M
-50%
2025
Income statement
DKK thousands
Item
2021
2022
2023
2024
2025
Revenue
-567
0
-1.206
-1.952
-5.463
Staff expenses
-166
-742
-1.969
-3.549
-3.124
EBITDA
-733
-1.909
-3.175
-5.500
-8.587
Depreciation & amort.
-3
-3
-3
-1
-0
EBIT
-736
-1.912
-3.178
-5.502
-8.587
Net financials
-179
-230
-337
-604
-1.261
Profit before tax
-915
-2.142
-3.515
-6.106
-9.848
Tax
27
-601
-934
-1.478
-2.272
Net profit
-943
-1.541
-2.581
-4.628
-7.576
Balance sheet
DKK thousands
Item
2021
2022
2023
2024
2025
Total assets
383
5.166
5.556
12.611
5.779
Equity
-3.902
-5.443
-8.024
-12.651
-20.227
Long-term debt
0
4.540
12.022
23.254
23.434
Short-term debt
4.284
6.069
1.558
2.009
2.572
Total debt
4.284
10.609
13.579
25.263
26.006
Financial ratios
5-year trend
EBITDA margin
-858720600.0%
This company
15.8%
Market median
5434940606% below market
2021
2025
Equity ratio
-350.0%
This company
38.2%
Market median
1016% below market
2021
2025
Return on equity
-757602200.0%
This company
18.4%
Market median
4117403361% below market
2021
2025
Net profit margin
-757602200.0%
This company
8.1%
Market median
9353113680% below market
2021
2025
Asset turnover
-0.95×
This company
1.12×
Market median
185% below market
2021
2025
Debt / equity
1.29×
This company
0.62×
Market median
108% above market
2021
2025
Annual reports & filings
Annual report 2025
Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
View
PDF
More on Cymab ApS
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
